VX17-659-105 Open Label A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Administered By

Awarded By

Contributors

Start/End

  • July 17, 2018 - July 16, 2023